西班牙65岁以上人群高剂量与佐剂流感疫苗的成本效用分析
本研究采用决策树模型评估西班牙65岁以上人群接种高剂量四价流感疫苗(HD-QIV)相比佐剂三价疫苗(aTIV)的公共卫生与经济收益,并纳入流感病例、就诊、住院和死亡等结局。结果显示转换策略可减少流感病例、就诊、住院和死亡,增加生命年和质量调整生命年,增量成本效用比为€24,353/QALY。敏感性分析表明结果稳健,HD-QIV至少具有成本效用。
要点
- 转换为HD-QIV可减少流感病例、就诊、住院和死亡。
- 增量成本效用比为€24,353/QALY,结果稳健。
- HD-QIV在西班牙65岁以上人群中至少具有成本效用。
核心结论
- 在西班牙65岁以上人群中,HD-QIV相比aTIV可减少流感病例、就诊、住院和死亡,并增加生命年和QALYs。
- HD-QIV的增量成本效用比为€24,353/QALY,敏感性分析表明结果稳健,至少具有成本效用。
研究设计与样本
- 决策树模型评估西班牙65岁以上人群接种HD-QIV相比aTIV的公共卫生和经济收益。
主要发现
- 转换策略可预防36,476例流感、5,143次全科医生就诊、1,054次急诊就诊、9,193例流感或肺炎住院和357例流感死亡。
- 增加3,514生命年和3,167质量调整生命年(QALYs)。
- 医疗费用增加€78,874,301,增量成本效用比为€24,353/QALY。
- 敏感性分析表明结果相当稳健。
关键数值与推荐
- 增量成本效用比为€24,353/QALY。
- 预防36,476例流感、5,143次全科医生就诊、1,054次急诊就诊、9,193例住院和357例死亡。
- 增加3,514生命年和3,167 QALYs。
- 医疗费用增加€78,874,301。
临床怎么用
- 在西班牙65岁以上人群中,可考虑将HD-QIV作为流感预防策略以降低疾病负担。
- 决策时需结合当地成本效用阈值评估HD-QIV的成本效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The normal ageing process is accompanied by immunosenescence and a progressive weakening of the immune system. High-dose inactivated influenza quadrivalent vaccine (HD-QIV) has shown greater immunogenicity, relative efficacy, and effectiveness than the standard-dose inactivated quadrivalent vaccine (SD-QIV). The aim of the study was to assess the cost-utility of an HD-QIV strategy compared with an adjuvanted trivalent inactivated vaccine (aTIV) strategy in the population above 65 years of age in Spain. METHODS: We evaluated the public health and economic benefits of alternatives by using a decision-tree model, which included influenza cases, visits to the general practitioner (GP), visits to the emergency department (ED), hospitalisations, and mortality related to influenza. We performed deterministic and probabilistic sensitivity analyses to account for both epidemiological and economical sources of uncertainty. RESULTS: Our results show that switching from aTIV strategy to HD-QIV would prevent 36,476 cases of influenza, 5,143 visits to GP, 1,054 visits to the ED, 9,193 episodes of hospitalisation due to influenza or pneumonia, and 357 deaths due to influenza - increasing 3,514 life-years and 3,167 quality-adjusted life-years (QALYs). Healthcare costs increase by €78,874,301, leading to an incremental cost-effectiveness ratio (ICER) of €24,353/QALY. The sensitivity analysis indicates that the results are rather robust. CONCLUSION: Our analysis shows that HD-QIV in people over 65 years of age is an influenza-prevention strategy that is at least cost-effective, if not dominant, in Spain. It reduces cases of influenza, GP visits, hospitalisations, deaths, and associated healthcare costs.
引用
- Redondo E, Drago G, López-Belmonte JL, et al. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine. Vaccine. 2021. PMID: 34344553. doi:10.1016/j.vaccine.2021.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。